Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| National Cancer Inst of Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Cancer Trials Group | NETWORK |
| Princess Margaret Hospital, Canada | OTHER |
Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| hypoxia measurement | Experimental | Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| hypoxia measurement | Procedure | transrectal oxygen measurement |
|
| Measure | Description | Time Frame |
|---|---|---|
| To determine the effect of neoadjuvant anti-androgen therapy on oxygenation of prostatic tumours | Trans-rectal ultrasound and measurement of tumor oxygenation | 8 weeks |
| Correlate level of tumor oxygenation with PSA level | PSA test (ug/L) | 8 weeks |
| Correlate level of tumor oxygenation with hemoglobin level | hemoglobin test (g/L) | 8 weeks |
| Correlate level of tumor oxygenation with prostate volume | prostate volume measurement | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| To study of the effect of neoadjuvant anti-androgen therapy on prostate tumour histopathology and gene expression, and correlation of these effects with changes in oxygenation. | 8 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Milosevic, MD | Princess Margaret Hospital, Canada | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Princess Margaret Hospital | Toronto | Ontario | M5G 2M9 | Canada |
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |